Problem:
The fabrication of novel biomaterials can suffer from difficulty of fabrication or lack of control over the end product (e.g. uniformity of size of nanoparticle). Further, modern techniques have been developed to functionalize novel biomaterials, but these methods often require time, cost, and effort in post processing.
Solution:
Taking a page from nature, Drs. Hammer and Lee have leveraged E. Coli to produce a plant protein (oleosin) whose normal biological role is to stabilize plant oil bodies. The result is a collection of nanoparticles of near uniform size.
Technology Overview:
The Hammer and Lee Labs have developed a method to produce oleosins and functionalized oleosins for a wide variety of applications from surfactants to a drug delivery vehicle to cancer cells. E. Coli can be can be transformed to fabricate oleosin or oleosin with additional molecules, including antibodies and GFP.
Advantages:
- Simple method to create functionalized nanoparticles (no post modification step)
- Uniform size of nanoparticle across range of desired sizes
- Nanoparticle size stable over days
Applications:
- Coatings, Surfactant, Emulsifier
- Vesicle/Nanoparticle
- Microbubble for Ultrasound Usage
- MRI Imaging/Theranostic Agent
Stage of Development:
Proof-of-concept testing
Desired Partnerships:
- License
- Sponsored research
Case ID:
X5754-tpNCS
Web Published:
3/18/2020
Patent Information:
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |